Targeted Nanoparticles Harboring Jasmine-Oil-Entrapped Paclitaxel for Elimination of Lung Cancer Cells

Abstract

Selectively targeted drug delivery systems are preferable chemotherapeutic platforms, as they specifically deliver the drug cargo into tumor cells, while minimizing untoward toxic effects. However, these delivery systems suffer from insufficient encapsulation efficiency (EE), encapsulation capacity (EC), and premature drug release. Herein, we coencapsulated paclitaxel (PTX) and Jasmine oil (JO) within PEG-PCL nanoparticles (NPs), with an average diameter < 50 nm, selectively targeted to non-small cell lung cancer (NSCLC) cells, via S15-aptamer (APT) decoration. JO was selected as an “adhesive” oily core to enhance PTX entrapment, as JO and PTX share similar hydrophobicity and terpenoid structure. JO markedly enhanced EE of PTX from 23% to 87.8% and EC from 35 ± 6 to 74 ± 8 µg PTX/mg PEG-PCL. JO also markedly increased the residual amount of PTX after 69 h, from 18.3% to 65%. Moreover, PTX cytotoxicity against human NSCLC A549 cells was significantly enhanced due to the co-encapsulation with JO; the IC50 value for PTX encapsulated within JO-containing APT-NPs was 20-fold lower than that for APT-NPs lacking JO. Remarkably, JO-containing APT-NPs displayed a 6-fold more potent cell-killing, relatively to the free-drug. Collectively, these findings reveal a marked synergistic contribution of JO to the cytotoxic activity of APT-NP-based systems, for targeted PTX delivery against NSCLC, which may be readily applied to various hydrophobic chemotherapeutics.

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

“…When using JO, encapsulation efficiency (EE) and encapsulation capacity (EC) are 87.7% and 74.2 ± 8.2 µg PTX per mg PP, respectively, versus 23% and 35.0 ± 6.0 µg PTX per mg PP when no JO was included. [ 83 ] Additionally, S15‐aptamer was added on the micelles for targeting NSCLC cells. Cell experiments against NSCLC A549 cells showed that the higher loaded PTX increased cytotoxicity with a decreased IC 50 value (20‐fold lower) when aptamer was labeled.…”

“…PEG-PCL micelles were modified by target agent S15-aptamer. [83] f) PTX enclosed in disulfide crosslinked micelles of di-lipoyl-glycerophosphorylcholine micelles (di-LA-PC). [86] g) PTX encapsulated in POEG-b-PVBA-b-PFTS (poly[oligo(ethylene glycol) methacrylate]-poly(4-vinylbenzyl azide)-poly(farnesylthiosalicylate), POFE) micelles labeled with radioactive 89 Zr and 64 Cu elements.…”

“…e) PTX mixed in jasmine oil, which were stabilized in micelles of PEG-PCL (carboxy-poly(ethylene glycol)-polycaprolactone). PEG-PCL micelles were modified by target agent S15-aptamer [83]. f) PTX enclosed in disulfide crosslinked micelles of di-lipoyl-glycerophosphorylcholine micelles (di-LA-PC) [86].…”

Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments

“…Moreover, targeted NMeds hold a considerable advantage over other traditional delivery methods. A rapidly increasing number of studies are being published searching for novel ligands to be incorporated onto the surface of NMeds to achieve specific delivery to organs [ 15 , 16 , 17 , 18 ], cells [ 19 , 20 ], or even intracellular locations [ 21 , 22 , 23 ], with several studies focusing on permeating the blood–brain barrier (BBB) for brain targeting [ 24 , 25 , 26 , 27 , 28 , 29 ]. When designing NMeds for GBM targeting, there are several barriers to overcome.…”

Development and evaluation of flubendazole inhalable nanoparticles for lung cancer treatmen

“…When the highest single agent (HSA) method was used to evaluate the effects of cytotoxicity at 300 nM for paclitaxel (57,86%) and the combined treatment (29,79%), the combination index was determined to be 3.5, suggesting that these concentrations exhibit a synergistic effect (DUARTE;VALE, 2022). Other studies revealed a synergistic effect of paclitaxel against A549 cells, such as the association with jasmine oil (ENGELBERG et al, 2021). The DNA-PK inhibitor M3814 also potentiated the paclitaxel cytotoxic effect, but this major dose reduction with a relatively low concentration of FBZ SD NC could significantly contribute to lowering the adverse effects of a paclitaxel chemotherapy regimen.…”